Joseph A.Goldman (Joe)

Practice Leader Tax

華盛頓 + 1.202.879.5437

聯絡

*Share

Joe Goldman is co-head of Jones Day's worldwide Tax Practice. He has 30 years of experience advising on the tax and business aspects of financial and international transactions. Joe counsels clients on M&A, collaboration and licensing agreements, post-acquisition integration of businesses, and financings and restructurings. He also advises clients on IRS audits and appeals.

Joe works regularly with clients in the life sciences and other high-value technology industries. He has provided tax advice on transactions worth hundreds of billions of dollars in the aggregate and has coordinated post-transaction legal entity restructurings and combinations around the world.

Joe's primary concentration is in cross-border taxation. He works with clients to maximize tax efficiency by developing specialized planning for foreign tax credits, transfer pricing, and profit repatriation. He also works with private equity clients, strategic investors, and hedge funds to structure their investments in the most tax-efficient manner.

Joe is a member of the American Bar Association (Taxation Section), the District of Columbia Bar, and the New York State Bar Association. He has lectured at conferences on numerous topics involving federal and international taxation.

影片

執業經驗

  • Sanofi and Janssen collaborate to develop vaccines for extra-intestinal pathogenic E. coliJones Day represented and supported Sanofi's in-house team in its strategic collaboration with Janssen Pharmaceuticals, now "Johnson & Johnson Innovative Medicine," in connection with a Co-Development, Co-Commercialization & License Agreement with Johnson & Johnson's Janssen Pharmaceuticals relating to the development and commercialization of vaccines for extra-intestinal pathogenic E. coli.
  • Five9 acquires Aceyus for $82 millionJones Day represented Five9, Inc. in its acquisition of 100% of the equity of Aceyus, Inc. for $82 million in cash.
  • Astellas acquires Iveric bioJones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.
  • Organon makes strategic investment in Claria MedicalJones Day advised Organon in the strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.
  • Incyte grants rights to CMS for ruxolitnib cream in China and Southeast AsiaJones Day represented Incyte Corporation in its Collaboration and License Agreement with CMS Aesthetics Limited for the development and commercialization of ruxolitinib cream, a novel cream formulation of Incyte’s selective JAK inhibitor ruxolitinib, for the treatment of autoimmune and inflammatory dermatologic diseases in Greater China and certain countries in Southeast Asia. 
  • Arc Holdings completes debt restructuring and recapitalizationJones Day represented Arc Holdings S.A.S. in a debt restructuring and recapitalization pursuant to its court approved conciliation agreement calling for debt forgiveness and a new loan of €108 million.
  • Incyte grants license to and collaborates with Zai Lab to develop and commercialize anti-PD1 pharmaceutical products in ChinaJones Day represented Incyte Corporation in its sublicense out to Zai Lab Limited of certain intellectual property rights to an anti-PD1 molecule licensed to Incyte from MacroGenics, Inc. globally in 2017 and which Incyte is actively developing in the U.S. and other jurisdictions outside of China.
  • Genomatica enters sponsored research agreement relating to biofuels, acquires technology from REGIJones Day represented Genomatica, Inc. in entering a sponsored research agreement for the development of advanced biofuels and acted as special IP counsel to Genomatica in its simultaneous acquisition of the assets of the life sciences division of Renewable Energy Group, Inc. ("REGI").
  • Incyte enters strategic collaboration agreement with Innovent for three clinical pharmaceuticals in ChinaJones Day represented Incyte Pharmaceuticals in its strategic collaboration and license agreement with Innovent Biologics for the regulatory development and commercialization in China of three clinical stage pharmaceutical candidates, a FGFR1/2/3 inhibitor, a JAK1 inhibitor, and a PI3K delta inhibitor, for treatment of hematological and oncological diseases.
  • Daiwa Securities Capital Markets Korea, DBS Bank Limited, Mizuho Securities Asia, and Standard Chartered Bank act as arrangers in $350 million Floating Notes offering of KAL ABS 23 Cayman LimitedJones Day acted as United States corporate and tax counsel to Daiwa Securities Capital Markets Korea Co., Ltd., DBS Bank Limited, Mizuho Securities Asia Limited, and Standard Chartered Bank, as joint lead arrangers, in connection with the offering of $350 million Secured Floating Rate Notes due 2021 of KAL ABS 23 Cayman Limited.
  • Patrón Tequila acquired by BacardiJones Day advised Patrón Spirits International AG ("Patrón") in connection with the acquisition by Bacardi Limited of all of the issued and outstanding shares of Patrón.
  • Demers Ambulances acquires Braun IndustriesJones Day represented Demers Ambulances, a Quebec-based designer, manufacturer, and distributor of ambulances in Canada, in connection with its acquisition of Braun Industries, Inc., a custom ambulance manufacturer serving customers throughout the U.S.
  • Ambry Genetics sold to joint venture formed by Konica Minolta and Innovation Network for up to $1.0 billionJones Day advised Ambry Genetics Corporation, a leading genetic testing corporation, in its sale to a newly formed joint venture between Konica Minolta, Inc. and Innovation Network Corporation of Japan for up to $1.0 billion (including earnouts).
  • Lam Research acquires Coventor, Inc.Jones Day advised Lam Research Corporation in its acquisition of Coventor, Inc., a leading provider of simulation and modeling solutions for semiconductor process technology, micro-electromechanical systems (MEMS), and the Internet of Things (IoT).
  • TDK acquires InvenSense for $1.3 billionJones Day advised TDK Corporation in its $1.3 billion acquisition of InvenSense, Inc.
  • Sumitomo Dainippon Pharma acquires Tolero Pharmaceuticals, Inc.Jones Day advised Sumitomo Dainippon Pharma Co. Ltd., a leading pharmaceutical company based in Japan, in its acquisition of Tolero Pharmaceuticals, Inc.
  • Celgene acquires Triphase Accelerator's first compound, MarizomibJones Day advised Celgene Corporation in the acquisition, through an affiliate, of Triphase Accelerator Corporation's assets related to its proteasome inhibitor, marizomib (MRZ), which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.
  • Specialty Silicone Fabricators sold to Trelleborg ABJones Day advised Specialty Silicone Fabricators, Inc., a California-based manufacturer of high-precision silicone components for medical technology original equipment manufacturers, in connection with the sale of all of the company's outstanding stock and real estate owned by certain entities related to shareholders of the company to Trelleborg AB, a Sweden-based leader in engineered polymer solutions.
  • Blue Point Capital Partners acquires Tierra Sol Ceramic TileJones Day acted as U.S. counsel to Blue Point Capital Partners and its portfolio company, Shnier-GESCO Limited Partnership (Shnier), in connection with the acquisition and related financing of Tierra Sol Ceramic Tile Ltd., a distributor of floor coverings in Canada and the United States.
  • BioMarin acquires global rights to Phenylketonuria (PKU) franchise from Merck Serono for $588.8 millionJones Day advised BioMarin Pharmaceutical Inc. in connection with its €525 million ($588.8 million) acquisition of the global rights to Kuvan® (sapropterin dihydrochloride) and pegvaliase from Merck Serono.
    •

    July 2024 Commentary

    Treasury Department Finalizes 1% Corporate Stock Buyback Tax Reporting Rules

    July 2024 Alert

    Supreme Court Upholds the Mandatory Repatriation Tax in Moore v. United States

    May 2024 Alert

    Internal Revenue Service Alters Its View on Section 355 Spin-Offs

    MAY 2024 Commentary

    New Guidance from the Treasury Department on 1% Corporate Stock Buyback Tax

    SEPTEMBER 2023 Alert

    Much-Anticipated Tax Reporting Regulations on Digital Asset Transactions Issued

    January 2023 Commentary

    Interim Guidance from the Treasury Department on the 1% Corporate Stock Buyback Tax

    October 2022 White Paper

    Digital Assets Defined: The Tax Code's Take

    August 2022 Commentary

    Inflation Reduction Act of 2022: Corporate Minimum Tax

    August 2022 Commentary

    Inflation Reduction Act Imposes New Tax on Corporate Stock Repurchases

    August 2022 Video

    JONES DAY PRESENTS®: Tax Implications of Telehealth as Remote Services Become the Norm
    顯示全部

    • February 7, 2018
      Tax Cut and Jobs Act: What it Means for American Business?
    • February 6, 2018
      How the Tax Cut and Jobs Act Impacts Your Business (A Legal Perspective)
    • February 6, 2018
      How the TCJA Impacts Your Business (A Technical Perspective)
    • February 6, 2018
      Jones Day's 2018 Speaker Series: The Tax Cuts and Job Act: What Does It Mean for American Business
    • January 25, 2018
      The Tax Cuts and Jobs Act: A Conference with the Government and Private Sector to Discuss the Legislation
    • May 4, 2017
      Business Tax Reform, Tax Council of the Manufacturers Alliance for Productivity & Innovation
    • April 20, 2017
      Preparing for a Sea Change: A Conference with the Government and Private Sector to Discuss Comprehensive Tax Reform
    • March 23, 2017
      Financial Services Regulation in the Trump Administration
    • March 17, 2017
      The Prospects For Business Tax Reform, FBA Tax Atlanta and the Atlanta Bar Tax Section
    • April 27, 2016
      International Tax Seminar for Detroit Chapter of Tax Executives Institute
    • June 22-23, 2015
      Ethics and the Tax Director, Tax Executives Institute, Region III Conference, Foxwoods Resort & Casino
    • May 1, 2015
      It's Not All About the Tax: Business and Transactional Considerations in Implementing an Inversion of Publicly-Traded Multinational Group
    • March 2015
      BIO Conference on International Taxation in the Biopharmaceutical Industry
    • 2009
      Tax for the Non-Tax Lawyer, CLE Summit
    • 2007
      2007 International Tax Planning for the U.S. Taxpayer, Tax Executives Institute
    • 2004
      Global Tax Planning for Intangibles, Tax Executives Institute
    • 2004
      Intangibles Tax Planning, Tax Executives Institute
    • 2004
      Cross-Border Finance, Tax Executives Institute

    *Before sending, please note:

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.